| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000018742 |
| Receipt No. | R000021685 |
| Scientific Title | Intervention trial for colorectal cancer prevention by endoscopic polypectomy in patients with familial adenomatous polyposis -2 |
| Date of disclosure of the study information | 2015/08/21 |
| Last modified on | 2021/08/24 (Ver. 7) |
| Basic information | ||
| Public title | Intervention trial for colorectal cancer prevention by endoscopic polypectomy in patients with familial adenomatous polyposis -2 | |
| Acronym | Intervention trial for colorectal cancer prevention by endoscopic polypectomy in patients with FAP -2 (J-FAPP Study 3-2) | |
| Scientific Title | Intervention trial for colorectal cancer prevention by endoscopic polypectomy in patients with familial adenomatous polyposis -2 | |
| Scientific Title:Acronym | Intervention trial for colorectal cancer prevention by endoscopic polypectomy in patients with FAP -2 (J-FAPP Study 3-2) | |
| Region |
|
|
| Condition | ||
| Condition | Patients with familial adenomatous polyposis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the usefulness and safety of thorough endoscopic polypectomy in patients with FAP. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase I,II |
| Assessment | |
| Primary outcomes | Whether or not a patient needs surgery on the large intestine during the intervention period. It includes not only the development of a polyp that cannot be removed endoscopically or that of large intestinal cancer, but also cases where a patient wishes to undergo resection of the large intestine because of discomfort of endoscopic examination, and cases where emergency surgery is performed because of perforation occurred during endoscopic treatment. |
| Key secondary outcomes | Presence or absence of the development of adverse events (perforation, hemorrhage, death from large intestinal cancer, and death from other causes), colorectal cancer, intramucosal carcinoma, or a tumor that is difficult to treat endoscopically. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Colonic polyps will be thoroughly removed by periodic colonoscopy. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who have (or had) 100 or more adenomas in the large intestine and who refused to undergo surgery despite of being advised to do so, and who are 16 years or older (parental consent is required in patients younger than 20 years). Patients who have (or had) 100 or more adenomas in the large intestine and who had part of the large intestine resected by surgery but still have 10 cm or more of the large intestine, and who are 16 years or older (parental consent is required in patients younger than 20 years). | |||
| Key exclusion criteria | Patients who are considered by their attending physicians to be ineligible to participate in the study because they have a serious disease in other organs, or because they cannot discontinue antiplatelet drugs, or for other reasons.
Patients who are receiving anticancer drugs. Patients with dense FAP in at least one-third of the large intestine. Patients in whom strict follow-up is difficult. |
|||
| Target sample size | 200 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kyoto Prefectural University of Medicine | ||||||
| Division name | Department of Molecular-Targeting Prevention | ||||||
| Zip code | 541-0042 | ||||||
| Address | 3-2-17-2F Imabashi, Chuo-ku, Osaka 541-0042, Japan | ||||||
| TEL | 06-6202-5444 | ||||||
| cancer@gol.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kyoto Prefectural University of Medicine | ||||||
| Division name | Department of Molecular-Targeting Prevention | ||||||
| Zip code | 541-0042 | ||||||
| Address | 3-2-17-2F Imabashi, Chuo-ku, Osaka 541-0042, Japan | ||||||
| TEL | 06-6202-5444 | ||||||
| Homepage URL | |||||||
| cancer@gol.com | |||||||
| Sponsor | |
| Institute | Kyoto Prefectural University of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japan Agency for Medical Research and Development |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Kyoto Prefectural University of Medicine |
| Address | 602-8566 Kyoto-shi, Kamigyo-ku Kajii-cho, Kawaramachi-Hirokoji, JAPAN |
| Tel | private |
| private | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 石川消化器内科(大阪府)
札幌医科大学附属病院(北海道) 愛知県がんセンター中央病院(愛知県) 国立がん研究センター中央病院(東京都) 兵庫医科大学病院(兵庫県) 徳島大学病院(徳島県) 広島大学病院(広島県) 石川県立中央病院(石川県) 大阪国際がんセンター(大阪府) 佐野病院(兵庫県) 栃木県立がんセンター(栃木県) 岩国医療センター(山口県) 四国がんセンター(愛媛県) 群馬中央病院(群馬県) がん研有明病院(東京都) 国立がん研究センター東病院(千葉県) 近畿大学医学部附属病院(大阪府) 東邦大学医療センター大橋病院(東京都) 京都大学医学部附属病院(京都府) 埼玉医科大学総合医療センター(埼玉県) 守口敬仁会病院(大阪府) 産業医科大学病院(福岡県) 帯広厚生病院(北海道) 九州大学病院(福岡県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000021685 |